Hormone Therapy Not Linked to Lung Cancer in Postmenopausal Women
In subgroup analyses, lower risk was seen with cumulative dosage of ≥401 mg or with therapy duration of five years or longer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.